Pharmacokinetic Considerations for Antimicrobial Therapy in Patients Receiving Renal Replacement Therapy

被引:0
|
作者
Federico Pea
Pierluigi Viale
Federica Pavan
Mario Furlanut
机构
[1] University of Udine,Institute of Clinical Pharmacology and Toxicology, Department of Experimental and Clinical Pathology and Medicine, Medical School
[2] University of Udine,Clinic of Infectious Diseases, Department of Medical and Morphological Research, Medical School
[3] University of Udine,Institute of Clinical Pharmacology and Toxicology, DPMSC
来源
Clinical Pharmacokinetics | 2007年 / 46卷
关键词
Renal Replacement Therapy; Linezolid; Meropenem; Therapeutic Drug Monitoring; Colistin;
D O I
暂无
中图分类号
学科分类号
摘要
Continuous renal replacement therapy (CRRT), particularly continuous venovenous haemofiltration (CVVH) and continuous venovenous haemodiafiltration (CVVHDF), are gaining increasing relevance in routine clinical management of intensive care unit patients. The application of CRRT, by leading to extracorporeal clearance (CLCRRT), may significantly alter the pharmacokinetic behaviour of some drugs. This may be of particular interest in critically ill patients presenting with life-threatening infections, since the risk of underdosing with antimicrobial agents during this procedure may lead to both therapeutic failure and the spread of breakthrough resistance. The intent of this review is to discuss the pharmacokinetic principles of CLCRRT of antimicrobial agents during the application of CVVH and CVVHDF and to summarise the most recent findings on this topic (from 1996 to December 2006) in order to understand the basis for optimal dosage adjustments of different antimicrobial agents.
引用
收藏
页码:997 / 1038
页数:41
相关论文
共 50 条
  • [31] Arteriovenous thrombosis in chronic renal failure patients receiving renal replacement therapy
    Shoaib, Munira
    Shamsi, Tahir S.
    Naz, Arshi
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2008, 18 (07): : 418 - 423
  • [32] CARDIAC ABNORMALITIES AND EXERCISE TOLERANCE IN PATIENTS RECEIVING RENAL REPLACEMENT THERAPY
    BULLOCK, RE
    AMER, HA
    SIMPSON, I
    WARD, MK
    HALL, RJC
    BRITISH MEDICAL JOURNAL, 1984, 289 (6457): : 1479 - 1484
  • [33] Antibiotic Dosing In Critically Ill Patients Receiving Renal Replacement Therapy
    Sime, Fekade Bruck
    Roberts, Jason A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (04) : 497 - 499
  • [34] Prevalence of patients receiving renal replacement therapy in El Salvador in 2014
    Garcia-Trabanino, Ramon
    Trujillo, Zulma
    Veronica Colorado, Ana
    Magana Mercado, Salvador
    Atilio Henriquez, Carlos
    NEFROLOGIA, 2016, 36 (06): : 631 - 636
  • [35] Hourly Fluid Balance in Patients Receiving Continuous Renal Replacement Therapy
    Naorungroj, Thummaporn
    Neto, Ary Serpa
    Zwakman-Hessels, Lara
    Yanase, Fumitaka
    Eastwood, Glenn
    Bellomo, Rinaldo
    BLOOD PURIFICATION, 2020, 49 (1-2) : 93 - 101
  • [36] The uptake of influenza vaccination by patients receiving renal replacement therapy.
    Wright, MJ
    Bel'eed, K
    Bhandari, S
    Eadington, D
    Farr, MJ
    Sellars, L
    KIDNEY INTERNATIONAL, 1999, 55 (05) : 2114 - 2114
  • [37] ASSESSMENT OF PHOSPHATE REPLACEMENT IN ADULT PATIENTS RECEIVING CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)
    Glass, Maresa
    Le, My
    CRITICAL CARE MEDICINE, 2009, 37 (12) : A410 - A410
  • [38] Technical considerations for renal replacement therapy in children
    Bunchman, Timothy E.
    Brophy, Patrick D.
    Goldstein, Stuart L.
    SEMINARS IN NEPHROLOGY, 2008, 28 (05) : 488 - 492
  • [39] Options for renal replacement therapy: Special considerations
    Becker, BN
    Stone, WJ
    SEMINARS IN NEPHROLOGY, 1997, 17 (03) : 176 - 187
  • [40] Antifungal Dosing Considerations in Patients Undergoing Continuous Renal Replacement Therapy
    Roger C.
    Sasso M.
    Lefrant J.Y.
    Muller L.
    Current Fungal Infection Reports, 2018, 12 (1) : 1 - 11